STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

MariMed (MRMD) director David R. Allen granted 176,389 RSUs as board fee compensation

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MariMed Inc. director David R. Allen reported an equity compensation grant in the form of restricted stock units (RSUs). On December 5, 2025, he received 176,389 RSUs, each of which converts into one share of MariMed common stock on a one-for-one basis. These RSUs were granted in lieu of cash for a portion of his fees for serving on the company’s Board of Directors.

The RSUs vest in full on December 15, 2025, according to the award agreement between MariMed and Allen. After this grant, he directly beneficially owned 299,755 shares of MariMed common stock and 176,389 RSUs, all held directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Allen David R

(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY

(Street)
NORWOOD MA 02062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 299,755 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 12/05/2025 A 176,389 (2) (2) Common Stock, par value $.001 per share 176,389 $0 176,389 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. The RSUs vest in full on December 15, 2025, in accordance with the terms of the award agreement between the Issuer and the Reporting Person.
Remarks:
The RSUs were granted in lieu of cash as payment for a portion of the Reporting Person's fees for serving on the Issuer's Board of Directors.
/s/ David R. Allen 12/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MariMed Inc. (MRMD) disclose in this filing?

The filing reports that director David R. Allen received a grant of 176,389 restricted stock units (RSUs) of MariMed Inc. on December 5, 2025.

How do the awarded RSUs for MariMed Inc. (MRMD) convert into common stock?

Each RSU converts into one share of MariMed common stock on a one-for-one basis, as stated in the explanation of responses.

When do David R. Allen’s RSUs in MariMed Inc. (MRMD) vest?

The 176,389 RSUs vest in full on December 15, 2025, in accordance with the terms of the award agreement between MariMed and the reporting person.

Why were these MariMed Inc. (MRMD) RSUs granted to the director?

The RSUs were granted in lieu of cash as payment for a portion of David R. Allen’s fees for serving on MariMed’s Board of Directors.

How many MariMed Inc. (MRMD) shares does the director own after this transaction?

Following the reported transaction, David R. Allen beneficially owned 299,755 shares of MariMed common stock and 176,389 RSUs, all held directly.

Is this MariMed Inc. (MRMD) filing for a single or multiple reporting persons?

The filing is indicated as Form filed by One Reporting Person, referring to director David R. Allen.
Marimed

OTC:MRMD

MRMD Rankings

MRMD Latest News

MRMD Latest SEC Filings

MRMD Stock Data

56.49M
280.32M
14.7%
0.24%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Norwood